Last reviewed 2026-04-19 · How we verify

glucosemonohydricum

University Hospital, Basel, Switzerland · FDA-approved active Small molecule

glucosemonohydricum is a Small molecule drug developed by University Hospital, Basel, Switzerland. It is currently FDA-approved.

At a glance

Generic name	glucosemonohydricum
Sponsor	University Hospital, Basel, Switzerland
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

glucosemonohydricum CI brief — competitive landscape report
glucosemonohydricum updates RSS · CI watch RSS
University Hospital, Basel, Switzerland portfolio CI

Frequently asked questions about glucosemonohydricum

What is glucosemonohydricum?

glucosemonohydricum is a Small molecule drug developed by University Hospital, Basel, Switzerland.

Who makes glucosemonohydricum?

glucosemonohydricum is developed and marketed by University Hospital, Basel, Switzerland (see full University Hospital, Basel, Switzerland pipeline at /company/university-hospital-basel-switzerland).

What development phase is glucosemonohydricum in?

glucosemonohydricum is FDA-approved (marketed).

Manufacturer: University Hospital, Basel, Switzerland — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing